- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
7
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
7 companies
Camurus
Market Cap: SEK 37.5b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 630.00
7D
-0.7%
1Y
-8.9%
Bonesupport Holding
Market Cap: SEK 15.0b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 228.00
7D
1.6%
1Y
-20.7%
BioArctic
Market Cap: SEK 29.9b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 337.20
7D
3.1%
1Y
41.2%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.84
7D
-0.7%
1Y
-13.6%
Egetis Therapeutics
Market Cap: SEK 3.2b
A pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
EGTX
SEK 6.80
7D
-6.1%
1Y
25.5%
Moberg Pharma
Market Cap: SEK 534.1m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 11.32
7D
3.5%
1Y
42.4%
AlzeCure Pharma
Market Cap: SEK 915.6m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.64
7D
-1.2%
1Y
69.8%